Ellie Im
Chief Medical OfficerDr. Ellie Im, M.D., is Chief Medical Officer of Crescent Biopharma, Inc. from April 2025. She was the Senior Vice President of Clinical Development & Oncology at Centessa Pharmaceuticals plc since October 2023. An experienced drug developer and leader in the oncology field, Dr. Im brings extensive expertise in clinical development and operations across various modalities, including antibody-drug conjugates (ADCs) and bispecific antibodies. Prior to her current role at Centessa, Dr. Im served as Senior Vice President of Clinical Development and Operations at Mersana Therapeutics Inc., where she led teams in clinical development and operations. Before that, she was the Clinical Development Lead and Senior Medical Director at Tesaro Inc., an oncology-focused company that was later acquired by GlaxoSmithKline plc, where she directed the clinical development for the drug JEMPERLI®. Dr. Im also held the position of Medical Director for Merck & Co., where she was the medical lead for the KEYNOTE-010 and KEYNOTE-021 studies, contributing significantly to the development of the KEYTRUDA® program. She is a medical oncologist, holding an MD from Catholic University College of Medicine in South Korea. Dr. Im is board certified in Internal Medicine and Medical Oncology and is an active member of the American Society of Clinical Oncology and the American Society of Hematology.
Positions
- Company NameCrescent Biopharma, Inc.Stock CodeCBIOPositionChief Medical OfficerColleagues
- JTJoshua T. BrummCEO & Director
- PEPeter Evan HarwinIndependent Chairman
- JMJonathan McNeillPresident & COO
- RWRichard William ScalzoChief Financial Officer
- RLRyan LynchSenior VP of Finance, Treasurer & Chief Accounting Officer
- ABAlexandra BalcomIndependent Director
- DCDavid Charles LubnerIndependent Director
- JVJonathan ViolinDirector
